Pacira BioSciences, Inc. 8K

Pacira BioSciences reported Q2 2026 results, closed the divestiture of its iovera° business to Zimmer Biomet, secured expanded UnitedHealthcare reimbursement for EXPAREL, advanced its PCRX-201 gene therapy program, and slightly revised 2026 guidance to reflect the asset sale.

Pacira BioSciences, Inc. filed a Form 8-K to furnish its second quarter 2026 financial results and to disclose the completion of the divestiture of its iovera° business to Zimmer Biomet Holdings, Inc. for up to $140 million (including a $70 million upfront payment, subject to adjustments, plus potential revenue-based milestone payments), which closed on July 31, 2026 and led to receipt of $73.6 million in cash at closing. The company reported Q2 2026 total revenue of $192.4 million (up 6% year over year), GAAP net income of $4.7 million versus a prior-year loss, non-GAAP net income of $29.5 million, and adjusted EBITDA of $48.7 million, with cash, cash equivalents, and investments of $251.0 million at quarter end. Pacira also announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL in outpatient settings, highlighted progress in its PCRX-201 gene therapy program (including transition to a scalable commercial manufacturing process, Phase 2 ASCEND Part B enrollment, and forthcoming Phase 1 publication), and modestly updated full-year 2026 revenue and non-GAAP SG&A guidance to reflect the iovera° divestiture while reiterating prior EXPAREL sales, non-GAAP gross margin, and non-GAAP R&D targets.

Filing Facts

CIK

1396814

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-052527

Alert Tier

7